Key Capital Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Key Capital Management's CRSP Position: Q3 2026 in Review
Key Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 5 shares worth $277. The position accounts for ﹤0.01% of the portfolio, ranked #777.
Key Capital Management first reported a position in CRSP in Q4 2025 and has held it in 4 quarters since. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Key Capital Management held 5 shares of CRISPR Therapeutics worth $277 as of Q3 2026.
- Key Capital Management left its CRISPR Therapeutics share count unchanged in Q3 2026.
- CRISPR Therapeutics made up ﹤0.01% of Key Capital Management's portfolio in Q3 2026, its #777 holding.
- Key Capital Management first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 4 quarters since.
- 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Key Capital Management's 13F filing for Q3 2026, filed 3 Nov 2026.